Reference

1. Yasui K, Sumida Y, Mori Y, Mitsuyoshi H, Minami M, Itoh Y, et al. Nonalco-holic steatohepatitis and increased risk of chronic kidney disease. Metabolism2011;60:735–9.
2. Majedul Hoque et al., Understanding Non Alcoholic Fatty Liver Disease: Causes, Symptoms and Treatment. International Journal of Research Publication and Reviews, Vol 4, no 9, pp 2084-2089 September 2023, doi: https://doi.org/10.55248/gengpi.4.923.92458
3. Bellentani, S. The epidemiology of non-alcoholic fatty liver disease. Liver international: official journal of the International Association for the Study of the Liver 37
4. Targher, G., Chonchol, M. B. & Byrne, C. D. CKD and nonalcoholic fatty liver disease. American journal of kidney diseases : the official journal of the National Kidney Foundation 64, 638-652, doi:10.1053/j.ajkd.2014.05.019 (2014).
5. Musso, G. et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS medicine 11, e1001680, doi:10.1371/journal.pmed.1001680 (2014).
6. Sun, D. Q. et al. (2020). Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD. Diabetes Metab 46, 288-295, doi:10.1016/j.diabet.2019.11.003
7. Park, H., Dawwas, G. K., Liu, X. & Nguyen, M. H. Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study. J Intern Med 286, 711-722, doi:10.1111/joim.12964 (2019)
8. Levey AS, Atkins R, Coresh J et al (2007) Chronic kidney disease as a global public health problem: approaches and initiatives– a position statement from kidney disease improving global outcomes. Kidney Int 72:247–259
9. Majedul Hoque. Prevalence of Renal Disease in Bangladesh. International Journal of Research, 2023, 10(9), 156-161, https://doi.org/10.5281/zenodo.8413719
10. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11:e1001680.
11. Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis 2014;64:638–52.
12. Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol 2017;13:297–310.
13. Paik, J. et al. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver international : official journal of the International Association for the Study of the Liver 39, 342-352, doi:10.1111/liv.13992 (2019).
14.  M. Hoque, T. Akram and S. N. Saha, “A Review on Methotrexate Used in Rheumatoid Arthritis”, International Journal of Research, vol. 10, no. 9, pp. 321–341, Sep. 2023, doi: https://doi.org/10.5281/zenodo.8396159
15. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62(Suppl.1):S47–64.
16. McCullough K, Sharma P, Ali T, Khan I, Smith WC, MacLeod A, et al. Measuring the population burden of chronic kidney disease: a systematic literature review of the estimated prevalence of impaired kidney function. Nephrol Dial Transplant 2012;27:1812–21.
17. Stringer S, Sharma P, Dutton M, Jesky M, Ng K, Kaur O, et al. The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. BMC Nephrol 2013;14:95.
18. Chang Y, Ryu S, Sung E, Woo HY, Oh E, Cha K, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in non-hypertensive and non-diabetic Korean men. Metabolism 2008;57:569–76.
19. Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008;19:1564–70
20. Arase Y, Suzuki F, Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, et al. The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern Med 2011;50:1081–90
21. Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care 2014;37:1729–36
22. Marcuccilli M, Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci2016;17:562.
23. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab 2008;93 (suppl 1):S74–S80
24. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363: 1341–1350.
25. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009;49:306–317
26. de Alwis NMW, Day CP. Nonalcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008;48 (Suppl. 1):S104–S112.
27. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16: 2134–2140
28. Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyl transferase concentrations and chronic kidney disease in the United States population. Findings from the National Health and Nutrition Examination Survey 2001–2006. Nutr Metab Cardiovasc Dis 2010;20:583–590
29. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009;205:533–537.
30. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010;5:2166–71.
31. Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial oxidative stress and antioxidants balance in fatty liver disease. Hepatol Commun 2018;2:1425–39
32. Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 2013;83:1029–41
33. Klisic A, Isakovic A, Kocic G, Kavaric N, Jovanovic M, Zvrko E, et al. Relation-ship between oxidative stress. Inflammation and dyslipidemia with fatty liver index in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes2018;126:371–8.
34. Xu G, Luo K, Liu H, Huang T, Fang X, Tu W. The progress of inflammation and oxidative stress in patients with chronic kidney disease. Ren Fail2015;37:45–9
35. Eslam, M. et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology international, doi:10.1007/s12072-020-10094-2 (2020)
36. Majedul Hoque et al., Advancing healthcare: Exploring recent innovations in drug delivery systems, International Journal of Multidisciplinary Research and Growth Evaluation, 2023, 4(5), 50-55, https://doi.org/10.54660/.IJMRGE.2023.4.5.50-55.
37. Yoneda M, Hasegawa T, Sato K. Vitamin E therapy for NAFLD/NASH. Nutrition. 2015;31:898–9.
38. Honda Y, Kessoku T, Sumida Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an openlabel, single-arm, multicenter, pilot study. BMC Gastroenterol. 2017;17:96
39. Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941–52.
40. Loomba R, Sirlin CB, Ang B, et al; San Diego Integrated NAFLD Research Consortium (SINC). Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61:1239-50